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Abstract
Illegal blood donation in the past decade has caused human immunodeﬁciency virus (HIV) outbreaks in some rural areas in China. Other
HIV-associated virus infections, such as those caused by human herpesvirus 8 (HHV8), in such areas are still not well deﬁned. In order to
explore HHV8 and hepatitis C virus (HCV) seroprevalence and potential risk factors in such areas, a cross-sectional study with 305 HIV-
positive and 315 HIV-negative subjects recruited from a rural county in Shanxi province was conducted, in which illegal blood collection
was reported. Interview questionnaires and serum testing were carried out with these participants. HCV and HHV8 seroprevalence were
found to be higher in the HIV-positive than in the HIV-negative group (76.4% vs. 2.5% and 15.4% vs. 4.8%, respectively), whereas the dif-
ference in HBV seroprevalence was not signiﬁcant. Co-infection with HCV and HHV8 was also more prevalent in the HIV-positive group.
HIV status (OR 2.71; 95% CI 1.16–6.30) and HBV status (OR 2.56; 95% CI 1.14–5.75) were independently associated with HHV8 infec-
tion. HIV status (OR 23.03; 95% CI 9.95–53.27) and blood/plasma selling history (OR 14.57; 95% CI 7.49–28.23) were strongly associated
with HCV infection. These ﬁndings demonstrate that both HHV8 and HCV infections are prevalent in this community. HIV infection is an
important risk factor for both HHV8 and HCV infection. HBV infection is associated with HHV8 infection but not with HCV infection. It
is possible that HHV8 and hepatitis B virus, but not HCV, have similar modes of transmission in this population.
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Introduction
Human herpesvirus 8 (HHV8), also known as Kaposi’s sar-
coma (KS)-associated herpesvirus, a member of the gamma
herpesvirus family, has consistently been found to be associ-
ated with all forms of KS. It is also associated with other lym-
phoproliferative diseases, such as primary effusion B-cell
lymphomas and multicentric Castleman’s disease [1]. HHV8
infection is not ubiquitous, and the prevalence varies between
different populations, but it is commonly found in human
immunodeﬁciency virus (HIV)-positive individuals. HHV8
seroprevalence is generally low to moderate in western coun-
tries, ranging from 3% to 23% [2–4]. However, in sub-Saharan
Africa, the seroprevalence can be as high as 50% in the
general population, and is even higher in the HIV-positive pop-
ulation [5–7]. Data from Asian countries suggest that HHV8
seroprevalence is generally low [8]. Several epidemiological
studies have been conducted to study the route of transmis-
sion and risk factors involved in the acquisition of HHV-8
infection [9–11]. Although salivary transmission has emerged
as one of the major routes of transmission, a recent
study conducted in Uganda has clearly demonstrated that
transmission via blood transfusion can occur, albeit inefﬁ-
ciently [12].
In addition to HHV8, unmonitored blood transfusion may
also increase the risk for acquiring hepatotropic viral infec-
tions, such as those caused by hepatitis C virus (HCV) and
hepatitis B virus (HBV). These viruses have been known to
share routes of transmission and risk factors with HIV. It has
also been reported that HCV co-infection is very common
among HIV-positive populations [13,14].
During the early 1990s, illegal plasma and blood collection
by commercial establishments was common in rural areas of
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central China, mainly as a means for rural farmers to aug-
ment their household income [15]. Practices such as pooling
of blood and re-infusion of red blood cells from donors with
compatible blood types exposed the blood donors to various
blood-borne pathogens, including HIV. This practice had led
to an outbreak of HIV in rural central China. Since the ﬁrst
outbreak of HCV infection among plasma donors in China in
1991, studies have shown a high seroprevalence of HCV in
the illegal blood donor population [13,16]. In contrast, very
little is known about HHV8 epidemiology in China, especially
in this unique high-risk population. A few studies on HHV8
prevalence in mainland China and in Xinjiang Uygur autono-
mous region in north-western China, which is an endemic
area for KS, have been reported [17,18]. No seroprevalence
studies of HHV8 have been conducted in areas of central
China where large numbers of illegal commercial blood/
plasma donors reside, even though high prevalence of HCV
and HIV has been observed in this area. The prevalence of
HHV8 in this population and its correlation with HIV, HBV
and HCV infection is not known.
Therefore, we conducted a cross-sectional epidemiological
study to ascertain the seroprevalence of HHV8 and HCV
among HIV-infected patients, and compared them with HIV-
negative individuals, in a rural area in Shanxi province of cen-
tral China. To our knowledge, this is the ﬁrst study to docu-
ment HHV8 seroprevalence in this population. These
ﬁndings will contribute to an enhanced awareness of HHV8
infection among these former blood donors.
Materials and Methods
Study cohort and sample collection
The present study was conducted in Yun-cheng city, a rural
prefecture area of Shanxi province in central China, a com-
munity that harbours a large number of former illegal blood
donors. The ﬁrst case from Yun-cheng city of HIV infection
in a plasma donor who had donated for commercial gain was
reported in 1996. From then, 626 HIV/AIDS cases had been
reported by the end of 2004. Of these, 246 patients had
died, and 43 were untraceable.
A total of 620 subjects were included in the present
study, and all samples were collected in late 2004 to early
2005 for an observational study on the quality of life in this
population. All samples were divided into two groups. The
ﬁrst was the HIV-positive group: All HIV-infected adults
were recruited from the local clinic, which offered free anti-
retroviral treatment as part of the national anti-HIV/AIDS
campaign. Only adults participated in this study, and 305 of
326 subjects (93.6%) gave consent. The other 21 patients
were unreachable, or refused to be interviewed or provide
blood samples. The second group was the HIV-negative
group: This group included 315 HIV-uninfected individuals who
were randomly selected from a local community-based adult
HIV screening programme from a village in the study area.
Venous blood was drawn from each study subject, coded
with a unique identiﬁcation number and then transferred to
the laboratory within 4 h of collection. Plasma was aliquoted
and stored at )70C. All assays were performed blindly, and
this study was approved by the Institutional Review Board of
Fudan University, Shanghai, China.
Serological testing
HIV. All samples were screened with commercial ELISA
(Abbott Laboratories, Chicago, IL, USA) for HIV antibodies,
according to the manufacturer’s protocol. Samples that tested
positive by ELISA were conﬁrmed by western blotting.
HCV and HBV. ELISA for HBV surface antigen and anti-HCV
IgG antibodies was conducted to determine HBV and HCV
infection status, according to the manufacturer’s protocol
(Wantai Biomedical, Beijing, China). All samples were assayed
in duplicate.
HHV8. Plasma samples were tested by monoclonal antibody-
enhanced immunoﬂuorescence assay, as reported previously
[19]. Brieﬂy, two HHV8 serology tests were used. First, BC-3
cells (an HHV8-positive and Epstein–Barr virus negative B-cell
line (American Type Culture Collection, Manassas, VA,
USA)), stimulated with tetradecanoyl phorbol acetate, were
ﬁxed, permeabilized and used for monoclonal-enhanced
immunoﬂuorescence assay. Second, Spodoptera frugiperda
clone 9, expressing three viral recombinant proteins, ORF73,
ORF65 and K8.1, was used for testing. The procedure was
similar to the BC-3 immunoﬂuorescence assay. A sample was
considered to be HHV-8-seropositive only if it was positive
at a standard serum dilution of 1 : 40 with both the BC-3 and
the S. frugiperda clone 9 assay. Each slide was read indepen-
dently by two experienced laboratory workers.
Statistical analysis
Original questionnaire data and laboratory results were
entered and managed with EpiData 3.0, and then transferred
to SPSS v11.5 (SPSS, Chicago, IL, USA) for further analysis.
Pearson chi-square test and univariate logistic regression
analyses were performed to explore correlates of HCV or
HHV8 seropositivity. Multiple logistic regression analyses
were conducted to identify risk factors for HCV or HHV8
prevalence after adjusting for potential confounders. ORs
with 95% CIs were generated to determine whether a vari-
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able was independently associated with HCV or HHV8 prev-
alence. All p-values £0.05 were considered to be statistically
signiﬁcant. The Mann–Whitney U-test was used to assess the
difference in geometric mean titres (GMTs) of HHV8
between the HIV-positive and HIV-negative groups. All statis-
tical analyses were carried out using SPSS software v11.5.
GraphPad Prism 5.0 (GraphPad, La Jolla, CA, USA) was used
to construct ﬁgures.
Results
Study cohort and characteristics
We enrolled 620 study participants (median age 43.0 years)
from Yun-cheng city for the purposes of this study. The Han
ethnic group is the major ethnic group in this province. The
differences in ethnicity, age group, marital status, education
and profession between the two groups were not signiﬁcant.
HIV-positive individuals were more likely to have multiple
sex partners and to have never used a condom. Seventy-
three per cent of the HIV-positive individuals sold blood/
plasma at least once, 16.1% had a history of receiving blood
transfusions, and 11.1% had a history of surgery. The major
demographic characteristics of all participants (305 HIV-posi-
tive and 315 HIV-negative subjects) are summarized in
Table 1.
HHV8 serology and associated risk factors
We conducted logistic regression analysis for risk factors
associated with HHV8 seroprevalence in this population.
HHV8 seroprevalence was signiﬁcantly higher in HIV-positive
than in HIV-negative individuals (15.4% vs. 4.8%, respectively;
p <0.001). The univariate analysis showed that HIV infection,
HBV infection and a history of blood/plasma donation were
associated with HHV8 infection. Multiple logistic regression
analysis indicated that HIV and HBV infection were indepen-
dently associated with HHV8 infection (OR 2.71,
95% CI 1.16–6.30, and OR 2.56, 95% CI 1.14–5.75, respec-
tively) (Table 2).
HHV8 antibody titre distribution
We also wanted to determine whether the GMT of HHV8
antibodies differed between the HIV-positive and HIV-nega-
tive groups. Therefore, plasma from all HHV8-seropositive
subjects was serially diluted and tested for IgG anti-HHV8
antibody titre. As shown in Fig. 1, the GMTs of HHV8 anti-
bodies were 417.3 (95% CI 319.5–545.1) for the HIV-posi-
tive group (n = 47) and 403.2 (95% CI 294.7–551.6) for the
HIV-negative group (n = 15). We did not observe any signiﬁ-
cant difference in the GMTs of HHV8 antibodies between
the HIV-positive group and the HIV-negative group (Mann–
Whitney U-test = 357.5, p 0.782).
HCV serology and associated risk factors
HCV seroprevalence was signiﬁcantly higher in the HIV-posi-
tive group than in the HIV-negative group (74.4% vs. 2.5%,
respectively; p <0.001). In the univariate analysis, gender,
condom usage, HIV status, history of selling blood/plasma
and history of surgery were found to be associated with
HCV infection. Multivariate analysis indicated that subjects
who were HIV-positive (OR 23.03; 95% CI 9.95–53.27) and
those who had a history of selling blood/plasma (OR 14.57;
95% CI 7.49–28.23) were more likely to be HCV-seroposi-
tive than those who were HIV-negative or had no history of
selling blood/plasma (Table 3).
Co-infection with HBV, HCV and HHV8
The overall seroprevalence of HBV, HCV and HHV8 among
the study subjects was 7.3% (45/620), 38.9% (241/620) and
10.0% (62/620), respectively. The seroprevalence of HBV,
HCV and HHV8 was 7.5% (23/305), 76.4% (233/305) and
15.4% (47/305), respectively, in the HIV-positive group, and
7.0% (22/315), 2.5% (8/315) and 4.8% (15/315), respectively, in




group, no. (%) Total (%)
Gender (p 0.002)
Male 165 (54.1) 132 (41.9) 297 (47.9)
Female 140 (45.9) 183 (58.1) 323 (52.1)
Ethnicity (p 0.078)
Han 302 (99.0) 315 (100.0) 617 (99.5)
Others 3 (0.9) 0 (0) 3 (0.5)
Age group (years) (p 0.029)
19–29 10 (3.3) 18 (5.7) 28 (4.5)
30–49 224 (73.4) 201 (63.8) 425 (68.6)
‡50 71 (23.3) 96 (30.5) 167 (26.9)
Marital status (p 0.720)
Married 292 (95.7) 302 (95.9) 594 (95.8)
Single 4 (1.3) 6 (1.9) 10 (1.6)
Divorced/widowed 9 (3.0) 7 (2.2) 16 (2.6)
Education (p 0.019)
Illiterate 26 (8.5) 14 (4.4) 40 (6.5)
Primary school 109 (35.7) 111 (35.3) 220 (35.5)
Middle school 154 (50.5) 156 (49.5) 310 (50.0)
High school or higher 16 (5.2) 34 (10.8) 50 (8.1)
Farmer (p 0.019)
Yes 290 (95.1) 284 (90.2) 574 (92.6)
No 15 (5.0) 31 (9.1) 46 (7.4)
Multiple sex partners (p 0.012)
Yes 16 (5.2) 5 (1.6) 21 (3.4)
No 289 (94.8) 310 (98.4) 599 (96.6)
Ever used condoms (p <0.001)
Yes 256 (83.9) 290 (93.8) 546 (88.9)
No 49 (16.1) 19 (6.0) 68 (11.1)
Ever had blood transfusion (p <0.001)
Yes 49 (16.1) 16 (5.1) 65 (10.5)
No 256 (83.9) 299 (94.9) 555 (89.5)
Ever donated blood/plasma (p <0.001)
Yes 223 (73.1) 0 (0) 223 (35.9)
No 82 (26.9) 315 (100) 397 (64.1)
Ever had surgery (p <0.001)
Yes 34 (11.1) 12 (3.8) 46 (7.5)
No 271 (88.9) 303 (96.2) 574 (92.5)
CMI Zhang et al. HHV8, HBV and HCV infections in rural China 397
ª2010 The Authors
Clinical Microbiology and Infection ª2010 European Society of Clinical Microbiology and Infectious Diseases, CMI, 17, 395–401
the HIV-negative group. The HIV-positive group and the HIV-
negative group had no signiﬁcant difference in the prevalence
of HBV (p 0.789), but had signiﬁcant differences in the preva-
lence of both HCV (p <0.001) and HHV8 (p <0.001). As
shown in Table 4, 54 (17.7%) HIV-positive individuals were
not co-infected with HBV, HCV or HHV8. However, 202
(66.2%) were co-infected with either one of the three viruses;
46 (15.1%) were co-infected with two viruses, and three
(1.0%) were co-infected with all three viruses. Among the 202
HIV-positive individuals who were co-infected with only one
of the above three viruses, 187 (92.6%) were co-infected with
HCV (Table 4). Among the 46 HIV-positive individuals with
co-infections with two of the three viruses, 31 (67.4%) were
co-infected with HCV and HHV8. Among HIV-negative indi-
viduals, the majority (87.3%) were negative for all three
viruses. Thirty-ﬁve (11.1% of 315) were co-infected with only
one other virus, of whom 51.4% were HBV-infected. Five
(1.6%) were co-infected with two other viruses (HBV, HCV
and/or HHV8), and none with all three viruses (Table 4).
Discussion
Given the continuing spread of the HIV/AIDS epidemic in
China, HHV8, which causes an important opportunistic
TABLE 2. Seroprevalence and cor-
relates of human herpesvirus 8





Univariate analysis Multivariate analysis
OR (95% CI) p-Value OR (95% CI)a p-Value
Gender
Male 26/297 (8.8) 1.00
Female 36/323 (11.1) 1.31 (0.77–2.22) 0.323
Age group (years)
19–29 2/28 (7.1) 1.00
30–49 46/425 (10.8) 1.58 (0.36–6.86) 0.543
‡50 14/167 (8.4) 1.19 (0.26–5.54) 0.825
Education
Illiterate 4/40 (10.0) 1.00
Elementary school 26/220 (11.8) 1.21 (0.40–3.66) 0.741
Middle school 28/310 (9.0) 0.89 (0.30–2.69) 0.842
High school or higher 4/50 (8.0) 0.78 (0.18–3.35) 0.741
Farmer
Yes 58/574 (10.1) 1.00
No 4/46 (8.7) 0.85 (0.29–2.45) 0.759
Ever married
Yes 61/610 (10.0) 1.00
No 1/10 (10.0) 1.00 (0.12–8.03) 1.000
Multiple sex partners
Yes 2/21 (9.5) 0.95 (0.22–4.16) 0.941
No 60/599 (10.0) 1.00
Ever used condoms
Yes 56/546 (10.3) 1.18 (0.49–2.85) 0.712
No 6/68 (8.8) 1.00
HIV infection status
Positive 47/305 (15.4) 3.64 (1.99–6.67) <0.001 2.71 (1.16–6.30) 0.021b
Negative 15/315 (4.8) 1.00 1.00
HBsAg
Positive 9/45 (20.0) 2.46 (1.12–5.39) 0.024 2.56 (1.14–5.75) 0.022b
Negative 53/575 (9.2) 1.00 1.00
Ever had blood transfusion
Yes 8/65 (12.3) 1.30 (0.59–2.87) 0.513
No 54/555 (9.7) 1.00
Ever donated blood/plasma
Yes 37/223 (16.6) 2.96 (1.73–5.60) <0.001 1.493 (0.71–3.18) 0.299
No 25/397 (6.3) 1.00 1.00
HBsAg, hepatitis B virus surface antigen; HIV, human immunodeﬁciency virus.
aOR and p-value were obtained with a multiple logistic regression model, which was adjusted for all demographic
variables listed in this table.
bp-values £0.05 were considered statistically signiﬁcant.
FIG 1. GMT of HHV8 antibodies in seropositive participants in the
HIV positive and negative groups. *Antibody titers were determined
by IFA based on BC3 slides. GMT for both groups were calculated
and compared. (Mann-Whitney U = 357.5, P = 0.782).
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infection, could become a major public health concern in
China. However, little information is available for the preva-
lence and transmission patterns of HHV8 among the Chinese
population, which could be of great importance for HHV8
prevention and control in China and for HIV/AIDS care in
particular. Therefore, studies on the modes of HHV8 trans-
mission and risk factors for HHV8 acquisition in China are
required.
The results from this study demonstrated a higher HHV8
seroprevalence (15.4%) in the HIV-positive group than in the
HIV-negative group (4.8%), which is consistent with other
serological studies on the epidemiology of HHV8 infection in
Shandong area, a neighbouring province in China [20]. HHV8
prevalence varies considerably between different regions of
the country. It is reported to be 19.3–46.6% in the general
population of Xinjiang, but only between 7.3% and 16.1% in
other provinces in China [17,18,20,21]. In support of other
studies conducted in China, we also found that HHV8 infec-
tion is not ubiquitous in China. As compared with results
from the Xinjiang area, our subjects have a relatively low
HHV8 prevalence. These differences may result from ethnic-
ity, socio-economic status, environmental characteristics and
hygiene practices. Previous data have shown that both ethnic
and socio-economic factors can inﬂuence HHV8 infection,
TABLE 3. Seroprevalence and cor-
relates of hepatitis C virus infec-





Univariate analysis Multivariate analysis
OR (95% CI) p-Value OR (95% CI)a p-Value
Gender
Male 142/297 (47.8) 1.00 1.00
Female 99/323 (30.7) 0.48 (0.35–0.67) <0.001 0.82 (0.45–1.50) 0.52
Age group (years)
19–29 7/28 (25.0) 1.00
30–49 167/425 (39.3) 1.94 (0.81–4.67) 0.138
‡50 67/167 (40.1) 2.01 (0.81–4.99) 0.133
Education
Illiterate 19/40 (47.5) 1.00
Elementary school 91/220 (41.4) 0.78 (0.40–1.53) 0.471
Middle school 123/310 (39.7) 0.73 (0.38–1.41) 0.344
High school or higher 8/50 (16.0) 0.22 (0.08–0.56) 0.002
Farmer
Yes 230/574 (40.1) 1.00 1.00
No 11/46 (23.9) 0.47 (0.23–0.94) 0.034 0.61 (0.17–2.17) 0.45
Ever married
Yes 237/610 (38.9) 1.00
No 4/10 (40.0) 1.05 (0.29–3.76) 0.941
Multiple sex partners
Yes 10/21 (47.6) 1.45 (0.61–3.46) 0.405
No 231/599 (38.6) 1.00
Ever used condoms
Yes 198/546 (36.3) 0.33 (0.20–0.56) 0.001 0.69 (0.28–1.76) 0.44
No 43/68 (63.2) 1.00 1.00
HIV infection status
Positive 233/305 (76.4) 124.19 (58.66–262.91) <0.001 23.03 (9.95–53.27) <0.001b
Negative 8/315 (2.5) 1.00 1.00
HBsAg
Positive 16/45 (35.6) 0.86 (0.46–1.62) 0.636
Negative 225/575 (39.1) 1.00
Ever had blood transfusion
Yes 28/65 (43.1) 1.22 (0.72–2.04) 0.463
No 213/555 (38.4) 1.00
Ever donated blood/plasma
Yes 202/223 (90.2) 88.29 (50.54–154.20) <0.001 14.57 (7.49–28.23) <0.001b
No 39/397 (9.8) 1.00 1.00
HBsAg, hepatitis B virus surface antigen; HIV, human immunodeﬁciency virus.
aOR and p-value were obtained by with a multiple logistic regression model, which was adjusted for all demographic
variables listed in this table.
bp-values £0.05 were considered statistically signiﬁcant.
TABLE 4. Summary of infection by hepatitis B virus (HBV),
hepatitis C virus (HCV) and human herpesvirus 8 (HHV8)







No. Prevalence (%) No. Prevalence (%)
None 54a 17.7 275 87.3
Single virus only
HBV 5a 1.6 18 5.7
HCV 187a 61.3 6 1.9
HHV8 10a 3.3 11 3.5
Two viruses
HBV + HCV 12a 3.9 1 0.3
HBV + HHV8 3a 1.0 3 1.0




3a 1.0 0 0
aThese infections are HHV8, HCV or HBV plus HIV.
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even in the Han population in Xinjiang, which was regarded
as a low-risk group throughout China, although the HHV8
prevalence in the same ethnic group is higher than in other
parts of China [17]. Interestingly, in our study, the HIV-posi-
tive group was found to have a slightly higher anti-HHV8
antibody titre than the HIV-negative group, although the dif-
ference was not statistically signiﬁcant.
As expected, we observed a very high level of co-infec-
tion with HCV in the HIV-positive group (76.4%) and a
much lower HCV prevalence in the HIV-negative group
(2.5%), which reﬂects the infection rate of the general pop-
ulation in the rest of China. As both HCV and HIV are
transmitted via blood, with HCV being more infectious than
HIV, it is not surprising that a high HCV co-infection rate
was detected in this study. Several studies on HCV co-
infection in former blood donors from other areas in China
have shown similar results, demonstrating that the HCV
prevalence can be as high as 78.6–86.3% among HIV-posi-
tive subjects [13,22,23]. Our results further conﬁrm that
HCV infection is primarily blood-borne and is of public
health importance for antiretroviral therapy in areas with
illegal plasma/blood donors.
The current study results suggest that HIV infection is
positively associated with both HHV8 and HCV infections.
Furthermore, there is an association between HHV8 and
HBV co-infection, but not between HHV8 and HCV co-infec-
tion. It is possible that factors associated with HBV transmis-
sion, such as close familial contact and sharing of hygiene
equipment, are also associated with HHV8 transmission. In
fact, an association between HHV8 and HBV infection has
been reported in previous studies [12,24]. As the HIV trans-
mission route and blood/plasma selling history were indepen-
dently associated with HCV but not with HHV8 and HBV, it
is likely that the HHV8 transmission route in this population
is not via blood and is different from that of HCV. The asso-
ciation between HIV and HHV8 co-infection could be attrib-
utable to immunosuppression, which rendered HIV-positive
individuals more susceptible to HHV8 infection. A previous
study on HHV8 transmission has shown that transmission of
HHV8 via blood is inefﬁcient [25]. In fact passive transfer of
HHV8 antibody was even suggested to have a protective
effect against HHV8 transmission [26]. In our study, no asso-
ciation between sexual behaviour, including multiple sex pat-
terns and condom use, and HHV8-positive status was
observed. This is also consistent with several previous stud-
ies demonstrating that heterosexual transmission of HHV8 is
rare [27,28]. Together, these ﬁndings support the hypothesis
that common routes of transmission are rarely shared by
HCV and HHV8 in this area, and this deserves further inten-
sive research.
In conclusion, both HHV8 and HCV infections are preva-
lent in this former illegal blood-donating community, with
HIV acting as an important factor in co-infection. Our data
demonstrate that HBV infection is associated with HHV8
infection but not with HCV infection. HHV8 and HBV, but
not HCV, may have similar modes of transmission in this
population. A number of studies have shown that HHV8 can
be detected and potentially be transmitted via saliva contact
[29,30], and it is possible that saliva plays an important role
in transmission in this study population. We are unable to
delineate this route, as saliva samples were not collected as
a part of this study. Further, prospective studies on HHV8
seroprevalence and more extensive risk factor analysis, such
as living arrangements, hygiene conditions and food-sharing
practices, are needed to explore the epidemiology of HHV8
infection in this population.
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